Calisotga Pharma (Seattle, WA) a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases closed a $26.2M Series A financing. Participants include Frazier Healthcare Venture, Alta Partners, Three Arch Partners, Amgen Ventures and Lilly Ventures.